ZNF799

Summary

ZNF799 (zinc finger protein 799, HGNC:28071) is a protein-coding gene on chromosome 19p13.2, encoding Zinc finger protein 799 (Q96GE5). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 90576 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 116 total
• MANE Select transcript: NM_001080821

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28071
Approved symbol	ZNF799
Name	zinc finger protein 799
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	HIT-40, MGC71805
Ensembl gene	ENSG00000196466
Ensembl biotype	protein_coding
OMIM	619916
Entrez	90576

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 retained_intron

ENST00000419318, ENST00000430385, ENST00000460935, ENST00000595766

RefSeq mRNA: 3 — MANE Select: NM_001080821 NM_001080821, NM_001322497, NM_001322498

CCDS: CCDS45989, CCDS82297

Canonical transcript exons

ENST00000430385 — 4 exons

Exon	Start	End
ENSE00001687822	12401068	12401271
ENSE00003586344	12393297	12393423
ENSE00003663983	12390016	12392206
ENSE00003680820	12392603	12392663

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 82.37.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3522 / max 21.8568, expressed in 742 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179307	1.3522	742

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.37	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.18	gold quality
endometrium	UBERON:0001295	78.38	gold quality
calcaneal tendon	UBERON:0003701	76.64	gold quality
granulocyte	CL:0000094	76.05	gold quality
placenta	UBERON:0001987	75.34	gold quality
left adrenal gland	UBERON:0001234	74.81	gold quality
left ovary	UBERON:0002119	74.76	gold quality
right ovary	UBERON:0002118	74.55	gold quality
right adrenal gland	UBERON:0001233	74.47	gold quality
left adrenal gland cortex	UBERON:0035825	74.47	gold quality
ovary	UBERON:0000992	74.29	gold quality
sural nerve	UBERON:0015488	74.22	gold quality
mucosa of transverse colon	UBERON:0004991	74.15	gold quality
islet of Langerhans	UBERON:0000006	74.07	gold quality
right adrenal gland cortex	UBERON:0035827	73.78	gold quality
adrenal gland	UBERON:0002369	73.62	gold quality
ventricular zone	UBERON:0003053	72.77	gold quality
leukocyte	CL:0000738	72.69	gold quality
rectum	UBERON:0001052	72.53	gold quality
right lobe of liver	UBERON:0001114	72.44	gold quality
monocyte	CL:0000576	72.31	gold quality
metanephros cortex	UBERON:0010533	72.05	gold quality
fallopian tube	UBERON:0003889	71.87	gold quality
cortex of kidney	UBERON:0001225	71.57	gold quality
smooth muscle tissue	UBERON:0001135	71.53	gold quality
pancreas	UBERON:0001264	71.15	gold quality
thoracic mammary gland	UBERON:0005200	71.14	gold quality
lymph node	UBERON:0000029	71.00	gold quality
cortical plate	UBERON:0005343	70.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

44 targeting ZNF799, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-3064-5P	99.26	66.13	1497

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp961	ENSMUSG00000052446
rattus_norvegicus	Zfp617	ENSRNOG00000049856

Paralogs (15): ZNF14 (ENSG00000105708), ZNF57 (ENSG00000171970), ZNF791 (ENSG00000173875), ZNF443 (ENSG00000180855), ZNF101 (ENSG00000181896), ZNF563 (ENSG00000188868), ZNF700 (ENSG00000196757), ZNF441 (ENSG00000197044), ZNF433 (ENSG00000197647), ZNF44 (ENSG00000197857), ZNF823 (ENSG00000197933), ZNF442 (ENSG00000198342), ZNF844 (ENSG00000223547), ZNF709 (ENSG00000242852), ZNF878 (ENSG00000257446)

Protein

Protein identifiers

Zinc finger protein 799 — Q96GE5 (reviewed: Q96GE5)

Alternative names: Zinc finger protein 842

All UniProt accessions (3): D3YTF2, Q96GE5, M0R0E1

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96GE5-1	1	yes
Q96GE5-2	2

RefSeq proteins (3): NP_001074290, NP_001309426, NP_001309427 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352, PF13912

UniProt features (24 total): zinc finger region 18, sequence variant 2, chain 1, domain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96GE5-F1	70.87	0.00

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 61 (showing top): chr19p13, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, RAPA_EARLY_UP.V1_DN, P53_DN.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, CEBPZ_TARGET_GENES, DACH1_TARGET_GENES, E2F2_TARGET_GENES, PRKDC_TARGET_GENES, ZNF350_TARGET_GENES, ZNF768_TARGET_GENES, MIR208B_5P, MIR208A_5P, MIR153_3P, MIR202_3P

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (5): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription cis-regulatory region binding	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

344 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF799	TAS2R46	P59540	479
ZNF799	SERPINB11	Q96P15	477
ZNF799	KHDC1	Q4VXA5	476
ZNF799	JCAD	Q9P266	439
ZNF799	SDK2	Q58EX2	419
ZNF799	KCNG4	Q8TDN1	395
ZNF799	BBS9	P78514	349
ZNF799	GRK4	P32298	324
ZNF799	RPL14	P50914	323
ZNF799	VPS33A	Q96AX1	280
ZNF799	BHMT	Q93088	279
ZNF799	DOK6	Q6PKX4	258
ZNF799	CCDC102B	Q68D86	254
ZNF799	ACADVL	P49748	252
ZNF799	RABEP2	Q9H5N1	247

IntAct

4 interactions, top by confidence:

A	B	Type	Score
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ECE1	ZNF799	psi-mi:“MI:0915”(physical association)	0.370
ZNF799	CSNK2A1	psi-mi:“MI:0914”(association)	0.350

BioGRID (2): ZNF799 (Affinity Capture-MS), ZNF799 (Affinity Capture-MS)

ESM2 similar proteins: A6NDX5, A6NK75, A6NNF4, A6NP11, B4DXR9, B7Z6K7, C9JN71, O43361, O75290, O75373, P0CJ79, P0DKX0, P17019, P17021, P17035, P17039, P35789, Q02386, Q03938, Q08AN1, Q13106, Q15928, Q3ZCX4, Q5R9F0, Q5SXM1, Q68EA5, Q6P9A1, Q6PDB4, Q6ZN06, Q6ZN08, Q6ZNG1, Q76KX8, Q86V71, Q86XN6, Q8IYB9, Q8N4W9, Q8NEP9, Q8TBZ8, Q8TC21, Q8TF32

Diamond homologs: A0JPK3, A2RRD8, A2VDQ7, A3KN32, A8MUZ8, A8MWA4, C9JN71, E9QAG8, O60384, O60765, O75820, P0CH99, P0CI00, P10076, P10755, P15621, P16374, P16415, P17017, P17024, P51523, P52737, P52740, Q06730, Q06732, Q08AG5, Q0D2J5, Q13106, Q13360, Q15928, Q15935, Q15973, Q32M78, Q3KP31, Q4R4C7, Q4R6J4, Q4R882, Q5R9F0, Q5RC79, Q5REI6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	111
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

608 predictions. Top by Δscore:

Variant	Effect	Δscore
19:12392659:CATTC:C	acceptor_gain	1.0000
19:12392662:TCC:T	acceptor_loss	1.0000
19:12392664:CTAAA:C	acceptor_loss	1.0000
19:12393291:CCTTA:C	donor_loss	1.0000
19:12393292:CTTA:C	donor_loss	1.0000
19:12393293:TTA:T	donor_loss	1.0000
19:12393294:TA:T	donor_loss	1.0000
19:12393295:A:C	donor_loss	1.0000
19:12393295:A:T	donor_loss	1.0000
19:12393296:C:CT	donor_loss	1.0000
19:12393296:CCTA:C	donor_gain	1.0000
19:12393434:CCACA:C	acceptor_gain	1.0000
19:12393435:C:CT	acceptor_gain	1.0000
19:12393435:C:T	acceptor_gain	1.0000
19:12393435:CACA:C	acceptor_gain	1.0000
19:12393437:C:CT	acceptor_gain	1.0000
19:12393438:A:C	acceptor_gain	1.0000
19:12393440:G:GC	acceptor_gain	1.0000
19:12393443:C:CT	acceptor_gain	1.0000
19:12393444:A:T	acceptor_gain	1.0000
19:12401064:GCAC:G	donor_loss	1.0000
19:12401065:CACC:C	donor_loss	1.0000
19:12401065:CACCA:C	donor_loss	1.0000
19:12401066:A:T	donor_loss	1.0000
19:12401067:C:CG	donor_loss	1.0000
19:12392204:CAT:C	acceptor_gain	0.9900
19:12392207:C:CC	acceptor_gain	0.9900
19:12392598:ATTAC:A	donor_loss	0.9900
19:12392599:TTACC:T	donor_loss	0.9900
19:12392600:TA:T	donor_loss	0.9900

AlphaMissense

4306 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:12390859:G:C	F513L	0.988
19:12390859:G:T	F513L	0.988
19:12390861:A:G	F513L	0.988
19:12390775:G:C	F541L	0.986
19:12390775:G:T	F541L	0.986
19:12390777:A:G	F541L	0.986
19:12390943:G:C	F485L	0.982
19:12390943:G:T	F485L	0.982
19:12390945:A:G	F485L	0.982
19:12391192:A:C	F402L	0.980
19:12391192:A:T	F402L	0.980
19:12391194:A:G	F402L	0.980
19:12390691:G:C	F569L	0.974
19:12390691:G:T	F569L	0.974
19:12390693:A:G	F569L	0.974
19:12391360:A:C	F346L	0.972
19:12391360:A:T	F346L	0.972
19:12391362:A:G	F346L	0.972
19:12391696:A:C	F234L	0.972
19:12391696:A:T	F234L	0.972
19:12391698:A:G	F234L	0.972
19:12393388:G:C	F13L	0.971
19:12393388:G:T	F13L	0.971
19:12393390:A:G	F13L	0.971
19:12391528:G:C	F290L	0.969
19:12391528:G:T	F290L	0.969
19:12391530:A:G	F290L	0.969
19:12391027:A:C	F457L	0.968
19:12391027:A:T	F457L	0.968
19:12391029:A:G	F457L	0.968

dbSNP variants (sampled 300 via entrez): RS1000356080 (19:12397842 A>G), RS1000442609 (19:12408996 T>C), RS1000665602 (19:12398096 A>G), RS1000836911 (19:12401246 T>A,C,G), RS1000897738 (19:12407214 G>A,C), RS1001045039 (19:12407611 CTCTT>C), RS1001520630 (19:12397586 G>A,C,T), RS1001583301 (19:12410073 G>A,T), RS1001596051 (19:12416461 C>A,T), RS1001725722 (19:12402360 C>T), RS1002134571 (19:12391824 G>A,T), RS1002177585 (19:12407289 C>A,T), RS1002230480 (19:12401873 T>C), RS1002381761 (19:12412827 G>T), RS1002442925 (19:12392142 G>A,C)

Disease associations

OMIM: gene MIM:619916 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST009439_9	Age-related cognitive decline (language) (slope of z-scores)	4.000000e-06
GCST010118_71	Type 2 diabetes	2.000000e-08
GCST90002393_642	Monocyte count	1.000000e-11
GCST90020029_16	Waist circumference adjusted for body mass index	1.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007710	cognitive decline measurement
EFO:0005091	monocyte count
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
arsenite	affects binding, decreases reaction	1
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	increases expression	1
di-n-butylphosphoric acid	affects expression	1
MT19c compound	increases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Nickel	decreases expression	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome